These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25256057)

  • 21. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.
    Dedhia P; Govil A; Mogilishetty G; Alloway RR; Woodle ES; Abu Jawdeh BG
    Transplant Proc; 2017; 49(1):188-192. PubMed ID: 28104134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of eculizumab in renal transplantation.
    Barnett AN; Asgari E; Chowdhury P; Sacks SH; Dorling A; Mamode N
    Clin Transplant; 2013; 27(3):E216-29. PubMed ID: 23516966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up.
    Okumi M; Omoto K; Unagami K; Ishida H; Tanabe K
    Int Urol Nephrol; 2016 May; 48(5):817-8. PubMed ID: 26865178
    [No Abstract]   [Full Text] [Related]  

  • 24. Protecting the kidney from complement: atypical haemolytic uraemic syndrome.
    Brocklebank V; Kavanagh D
    Clin Med (Lond); 2014 Dec; 14 Suppl 6():s89-94. PubMed ID: 25468928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eculizumab use in kidney transplantation.
    Johnson CK; Leca N
    Curr Opin Organ Transplant; 2015 Dec; 20(6):643-51. PubMed ID: 26536427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.
    Krishnan AR; Siva B; Chakera A; Wong G; Wong D; Lim WH
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():28-31. PubMed ID: 28176477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation.
    Pelicano MB; de Córdoba SR; Diekmann F; Saiz M; Herrero S; Oppenheimer F; Campistol JM
    Transplantation; 2013 Aug; 96(4):e26-9. PubMed ID: 23958887
    [No Abstract]   [Full Text] [Related]  

  • 28. Eculizumab in renal transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Rabant M; Loupy A; Timsit MO; Anglicheau D
    Transplant Rev (Orlando); 2013 Jul; 27(3):90-2. PubMed ID: 23747093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful living-related renal transplantation in a patient with factor H antibody-associated atypical hemolytic uremic syndrome.
    Hofer J; Giner T; Cortina G; Jungraithmayr T; Masalskiene J; Dobiliene D; Mitkiene R; Pundziene B; Rudaitis S
    Pediatr Transplant; 2015 Aug; 19(5):E121-5. PubMed ID: 26037622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.
    Carter S; Hewitt I; Kausman J
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():7-10. PubMed ID: 28176479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eculizumab-related progressive multifocal leukoencephalopathy.
    Gómez-Cibeira E; Ivanovic-Barbeito Y; Gutiérrez-Martínez E; Morales E; Abradelo M; Hilario A; Ramos A; Ruiz-Morales J; Villarejo-Galende A
    Neurology; 2016 Jan; 86(4):399-400. PubMed ID: 26718572
    [No Abstract]   [Full Text] [Related]  

  • 32. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.
    Kim MS; Prasad V
    JAMA Intern Med; 2020 Feb; 180(2):315-317. PubMed ID: 31657842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab.
    Chonat S; Chandrakasan S; Kalinyak KA; Ingala D; Gruppo R; Kalfa TA
    Br J Haematol; 2016 Nov; 175(4):744-747. PubMed ID: 27870017
    [No Abstract]   [Full Text] [Related]  

  • 34. Eculizumab in Renal Transplantation: A 2017 Update.
    Grenda R; Durlik M
    Ann Transplant; 2017 Sep; 22():550-554. PubMed ID: 28894081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.
    Reuter S; Heitplatz B; Pavenstädt H; Suwelack B
    Transplantation; 2013 Nov; 96(10):e74-6. PubMed ID: 24247905
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of Eculizumab in atypical hemolytic uremic syndrome after renal transplantation].
    Teixeira CI; Mota RG; Afonso BG; Carneiro TV; Meira GS; Mendonça DU
    J Bras Nefrol; 2015; 37(1):127-30. PubMed ID: 25923760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.
    Volokhina EB; van de Kar NC; Bergseth G; van der Velden TJ; Westra D; Wetzels JF; van den Heuvel LP; Mollnes TE
    Clin Immunol; 2015 Oct; 160(2):237-43. PubMed ID: 26111482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab.
    Juega-Mariño FJ; Sala N; López D; Cañas L; Bonet J; Lauzurica R
    Nefrologia; 2016; 36(3):328-9. PubMed ID: 27012439
    [No Abstract]   [Full Text] [Related]  

  • 39. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.
    Nester C; Stewart Z; Myers D; Jetton J; Nair R; Reed A; Thomas C; Smith R; Brophy P
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1488-94. PubMed ID: 21617085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient.
    Jehn U; Altuner U; Pavenstädt H; Reuter S
    Transpl Int; 2022; 35():10846. PubMed ID: 36262114
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.